CliffBio
biologic

Pulmozyme

dornase alfa

Loss of exclusivityDecember 2005projected — 12-year biologic exclusivity estimate
CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand namePulmozyme
Active ingredientdornase alfa
Strength2.5MG/2.5ML (1MG/ML)
Dosage formSolution
RouteInhalation
ModalityBiologic
FDA approvalDecember 1993
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Pulmozyme patent cliff — loss of exclusivity December 2005 | CliffBio